Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
| ▸ | OGG1 | O15527 | 1/20 | 0.50 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29071120 | 0.81 | HSD17B3 (0.55) | ALDH1A1MAPTGAAHPGDPOLB | |
| SCHEMBL22876929 | 0.81 | NPC1 (0.59) | GSK3BHDAC1HDAC6ALDH1A1MAPT | |
| SCHEMBL12098895 | 0.81 | GSK3B (0.59) | GSK3BHDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL14817828 | 0.80 | KMT2A (0.56) | GSK3BHDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL2295966 | 0.80 | GSK3B (0.53) | GSK3BHDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL3323642 | 0.80 | GSK3B (0.53) | GSK3BHDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL1305020 | 0.80 | GSK3B (0.70) | GSK3BHDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL2708888 | 0.79 | GSK3B (0.57) | GSK3BHDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL2299475 | 0.79 | NPC1 (0.55) | ALDH1A1MAPTCES2CES1KMT2A | |
| SCHEMBL22873813 | 0.79 | ALDH1A1 (0.45) | HDAC1HDAC3HDAC2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117447847-B | Wear-resistant rubber composite material and preparation method thereof | 河北能一重型机械配件有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-117447847-A | Wear-resistant rubber composite material and preparation method thereof | 河北能一重型机械配件有限公司 | 2024-01-26 | — | — | CN | claimed |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | claimed |
| US-4386053-A | IMPREGNATION OF SUBSTRATE WITH ORGANIC PEROXIDE, CHROMOGEN, BUFFER AND STABILIZER | TERUMO CORPORATION (JP) | 1983-05-31 | — | — | US | claimed |
| CN-117447847-B | Wear-resistant rubber composite material and preparation method thereof | 河北能一重型机械配件有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117447847-A | Wear-resistant rubber composite material and preparation method thereof | 河北能一重型机械配件有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3939964-A1 | COMBINATIONS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-7994315-B2 | Intermediate compound for synthesizing pharmaceutical agent and production method thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| EP-2221305-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-2221304-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | disclosed |
| US-4386053-A | IMPREGNATION OF SUBSTRATE WITH ORGANIC PEROXIDE, CHROMOGEN, BUFFER AND STABILIZER | TERUMO CORPORATION (JP) | 1983-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | GSK3B 17/4885HDAC1 371/4885HDAC8 445/4885 |
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | GSK3B 54/4885HDAC1 1582/4885HDAC8 2853/4885 |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | GSK3B 54/4885HDAC1 1582/4885HDAC8 2853/4885 |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | GSK3B 54/4885HDAC1 1582/4885HDAC8 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.